Hualan Biological Engineering Inc.
002007
Pozycja w akcjach
#4385
Hualan Biological Engineering Inc. operates as a biopharmaceutical company,... Hualan Biological Engineering Inc. operates as a biopharmaceutical company, specializing in the research, development, production, and commercialization of a diverse portfolio of medical products within the People's Republic of China. Its offerings span plasma-derived therapies, various viral and bacterial vaccines, recombinant proteins, and other advanced biologics. The company's extensive range of plasma products includes essential components like human albumin, a broad spectrum of human immunoglobulins (such as intravenous, rabies, hepatitis B, and tetanus formulations), and vital coagulation factors like human prothrombin complex and factor VIII. Hualan also provides specialized solutions such as lyophilized human thrombin for external use and surgical fibrin glue. In its vaccine division, Hualan offers critical immunizations, including several influenza vaccines (e.g., split virus, A H1N1, and quadrivalent forms), recombinant hepatitis B vaccine, and ACYW135 meningococcal polysaccharide vaccine. The company actively pursues strategic collaborations with key scientific organizations, most notably the Chinese Academy of Sciences, as well as other esteemed research institutes and enterprises. Established in 1992, Hualan Biological Engineering Inc. is headquartered in Xinxiang, People's Republic of China.
Cena akcji
$1.92
Kapitalizacja rynkowa
$3.50B
Zmiana (1 dzień)
-1.39%
Zmiana (1 rok)
-19.45%
Kraj
CN
Handel Hualan Biological Engineering Inc. (002007)
Kategoria
Healthcare
Wskaźnik P/B dla Hualan Biological Engineering Inc. (002007)
Wskaźnik P/B na dzień October 2026 TTM: 2.13
Według najnowszych raportów finansowych i ceny akcji Hualan Biological Engineering Inc., obecny wskaźnik P/B (TTM) wynosi 2.13. Na koniec 2024 wynosił 2.59.
Historia wskaźnika P/B dla Hualan Biological Engineering Inc. od 2001 do 2026
Wskaźnik P/B na koniec każdego roku
| Rok | Wskaźnik P/B | Zmień |
|---|---|---|
| 2026 (TTM) | 2.13 | -11.18% |
| 2025 | 2.40 | -7.39% |
| 2024 | 2.59 | -27.01% |
| 2023 | 3.55 | -10.48% |
| 2022 | 3.97 | -37.62% |
| 2021 | 6.36 | -37.60% |
| 2020 | 10.20 | 35.87% |
| 2019 | 7.51 | 49.25% |
| 2018 | 5.03 | -10.18% |
| 2017 | 5.60 | -28.94% |
| 2016 | 7.88 | 12.72% |
| 2015 | 6.99 | 22.97% |
| 2014 | 5.69 | 5.58% |
| 2013 | 5.38 | 15.44% |
| 2012 | 4.66 | -23.42% |
| 2011 | 6.09 | -52.62% |
| 2010 | 12.85 | 7.25% |
| 2009 | 11.99 | 55.58% |
| 2008 | 7.70 | -57.54% |
| 2007 | 18.15 | 186.87% |
| 2006 | 6.33 | 322.88% |
| 2005 | 1.50 | 22.78% |
| 2004 | 1.22 | -75.16% |
| 2003 | 4.90 | -27.47% |
| 2002 | 6.76 | -30.90% |
| 2001 | 9.79 | 0.00% |
Wskaźnik P/B dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/B | Różnica wskaźnika P/B | Kraj |
|---|---|---|---|
| 6.251 | 193.25% |
US
|
|
| 13.6307 | 539.46% |
US
|
|
| 4.4521 | 108.86% |
AU
|
|
| 3.2932 | 54.49% |
BE
|
|
| 6.3632 | 198.52% |
NL
|
